Simcere Pharma Wins Promotion Rights for PrimeGenX's Atopic Dermatitis Drug

MT Newswires Live

Jun 02

Simcere Pharmaceutical (HKG:2096) entered into an exclusive promotion service agreement with PrimeGenX Therapeutics for Pumecitinib Gel, a Monday Hong Kong bourse filing said.

Under the agreement, Simcere obtained exclusive promotion rights for the drug's dermatology indications in mainland China, Hong Kong, and Macau.

Pumecitinib Gel is described as the "world's first" JAK inhibitor gel for atopic dermatitis and is also being developed for additional dermatology indications, including atopic dermatitis in children aged 2 to 11, prurigo nodularis, and non-segmental vitiligo, according to the filing.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/news/2640995678"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2640995678\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2640995678?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-06-02 09:17","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2640995678","market":"hk","top_or_hot":-1,"title":"Simcere Pharma Wins Promotion Rights for PrimeGenX's Atopic Dermatitis Drug","media":"MT Newswires Live","content":"<html><body><p> <a href=\"https://laohu8.com/S/SMHGF\">Simcere Pharmaceutical</a> (HKG:2096) entered into an exclusive promotion service agreement with PrimeGenX <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> for Pumecitinib Gel, a Monday Hong Kong bourse filing said.</p><p>Under the agreement, Simcere obtained exclusive promotion rights for the drug's dermatology indications in mainland China, Hong Kong, and Macau.</p><p>Pumecitinib Gel is described as the \"world's first\" JAK inhibitor gel for atopic dermatitis and is also being developed for additional dermatology indications, including atopic dermatitis in children aged 2 to 11, prurigo nodularis, and non-segmental vitiligo, according to the filing.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Simcere Pharma Wins Promotion Rights for PrimeGenX's Atopic Dermatitis Drug</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nSimcere Pharma Wins Promotion Rights for PrimeGenX's Atopic Dermatitis Drug\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2026-06-02 09:17</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> <a href=\"https://laohu8.com/S/SMHGF\">Simcere Pharmaceutical</a> (HKG:2096) entered into an exclusive promotion service agreement with PrimeGenX <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> for Pumecitinib Gel, a Monday Hong Kong bourse filing said.</p><p>Under the agreement, Simcere obtained exclusive promotion rights for the drug's dermatology indications in mainland China, Hong Kong, and Macau.</p><p>Pumecitinib Gel is described as the \"world's first\" JAK inhibitor gel for atopic dermatitis and is also being developed for additional dermatology indications, including atopic dermatitis in children aged 2 to 11, prurigo nodularis, and non-segmental vitiligo, according to the filing.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1583","symbol_name":"高瓴概念","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2640995678","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2640995678","pubTimestamp":1780363033,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Simcere Pharmaceutical  entered into an exclusive promotion service agreement with PrimeGenX Therapeutics for Pumecitinib Gel, a Monday Hong Kong bourse filing said.Under the agreement, Simcere obtained exclusive promotion rights for the drug's dermatology indications in mainland China, Hong Kong, and Macau.Pumecitinib Gel is described as the \"world's first\" JAK inhibitor gel for atopic dermatitis and is also being developed for additional dermatology indications, including atopic dermatitis in children aged 2 to 11, prurigo nodularis, and non-segmental vitiligo, according to the filing.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK1583":"高瓴概念","BK1191":"制药","02096":"先声药业"},"translate_title":"先声药业获PrimeGenX特应性皮炎药物推广权","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02096":1},"content_text":"Simcere Pharmaceutical (HKG:2096) entered into an exclusive promotion service agreement with PrimeGenX Therapeutics for Pumecitinib Gel, a Monday Hong Kong bourse filing said.Under the agreement, Simcere obtained exclusive promotion rights for the drug's dermatology indications in mainland China, Hong Kong, and Macau.Pumecitinib Gel is described as the \"world's first\" JAK inhibitor gel for atopic dermatitis and is also being developed for additional dermatology indications, including atopic dermatitis in children aged 2 to 11, prurigo nodularis, and non-segmental vitiligo, according to the filing.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}